The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis

Approximately 20-50% patients with chronic phase chronic myeloid leukemia (CML-CP) treated with tyrosine kinase inhibitors (TKI) or with myelofibrosis (MF) treated with ruxolitinib develop grade ≥3 thrombocytopenia needing treatment interruptions and dose reductions. We conducted a non-randomized, p...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoukier, Mahran, Borthakur, Gautam, Jabbour, Elias, Ravandi, Farhad, Garcia-Manero, Guillermo, Kadia, Tapan, Matthews, Jairo, Masarova, Lucia, Naqvi, Kiran, Sasaki, Koji, Verstovsek, Srdan, Cortes, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561288/
https://www.ncbi.nlm.nih.gov/pubmed/33054123
http://dx.doi.org/10.3324/haematol.2020.260125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561288/
https://www.ncbi.nlm.nih.gov/pubmed/33054123
http://dx.doi.org/10.3324/haematol.2020.260125

Ejemplares similares